As part of the deal, Blackstone will acquire 50 percent of the royalties owed to Alnylam on global sales of inclisiran, a twice-a-year, subcutaneously injected RNAi therapeutic for the treatment of hypercholesterolemia. Other components of the deal include up to $750 million in a first lien senior secured term loan led by GSO; up to $150 million from Blackstone Life Sciences for development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent) and $100 million purchase of Alnylam common stock.
Inclisiran is currently under review by the U.S. Food and Drug Administration. Results from two phase 3 trials, ORION-10 and ORION-11 were published in The New England Journal of Medicine in March of 2020. the Both trials showed treatment with inclisiran led to reductions in LDL cholesterol levels of approximately 50%.
Alnylam and The Medicines Company entered into a strategic alliance for inclisiran in 2013. Novartis acquired inclisiran when it purchased The Medicines Company for $9.7 billion in November of 2019.